Pay in 4 interest-free payments of $5.42 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Can Akkermansia support GLP-1 therapy outcomes
Beyond weight reduction, the same trial reported several additional metabolic outcomes as secondary or exploratory endpoints: Improved glycaemic control reductions in HbA1c levels were observed in participants with type 2 diabetes in a separate Phase 2 cohort [3] [4] Reduced waist circumference suggesting a decrease in visceral (abdominal) fat, which is associated with cardiovascular risk Improvements in lipid profiles including reductions in triglycerides Potential signal for benefit in metabolic-associated steatotic liver disease (MASLD) based on the glucagon receptor's proposed role in hepatic fat metabolism
Electrons want to exist in pairs
Continuous ofatumumab treatment up to 7 years shows a consistent safety profile and delays disability progression in people with relapsing multiple sclerosis
US$ 26.63
US$ 27.43
US$ 27.77
US$ 23.98
